Novo Nordisk (NVO)

[winston]

not vested

THE ELECTION IS CRUSHING THIS SECTOR

Today's chart shows that one of the market's greatest "boom and bust" sectors is in "bust" mode...

As regular readers know, folks love the idea of investing in the next blockbuster drug or "miracle pill." This draws in speculative money flows. As we often say... get in early on the booms, avoid the busts, and you can make great money in biotech.

But right now, biotech is struggling. We can see this by looking at Novo Nordisk (NVO). The company is the world leader in insulin and diabetes care and the world's largest producer of industrial enzyme products.

The pricing of biotech drugs is a hot topic right now. And biotech firms are drawing increasing scrutiny over their cost. A new White House regime could mean lower profits and greater oversight in the sector.

Shares of NVO are feeling the pressure, down 31% this year. If the government gets more involved in pricing drug treatments, biotech may continue to slide...

Source: Daily Wealth

[winston]

not vested

This Stock Yields 4.2% and is Currently Undervalued

By Richard Robinson

Diabetes afflicts more than 430 million people worldwide. That’s a 300% increase from 1980 levels.

And that number is expected to grow to 645 million by 2040.

Novo Nordisk (NYSE: NVO) is a Danish company with a market cap of $90 billion. They have manufactured insulin since 1923. The company controls 50% of the global market for insulin and 25% of the diabetes industry.

The company generates revenues of $16 billion annually. A little more than half of that comes from its North American operations. That’s not surprising given the prevalence of obesity in the United States and Canada.

Insulin sales and obesity care generate nearly about 79% of the company’s revenues. The remaining 21% comes from the company’s biopharma sales for human growth hormone products and hemophilia treatments.

Novo Nordisk has grown its revenues at compound annual growth rate (CAGR) of 12.9% since 2012. That trend has continued this year, with revenues in the first half of 2016 growing by 5%.

The company’s operating margin, at 41%, ranks in the top 10% of public companies in the world.

Risks To Consider: NVO could continue to face U.S. price pressures on its line of insulin drugs — and a lack of product diversification could affect the stock price further.

Source: Wall Street Daily

http://dailytradealert.com/2016/11/23/t ... dervalued/

[winston]

European Stocks to Buy for Big Dividends: Novo Nordisk (NVO)

Dividend Yield: 2.6%

When it comes to European stocks of multinationals, the healthcare sector is where the content really shines. And shining brightest of all is Novo Nordisk A/S (ADR) (NYSE:NVO).

NVO has plenty of exposure to various therapies and drugs, but where it really makes its money is from diabetes.

Diabetes has become a worldwide epidemic with new instances rising every year. Increased sedentary lifestyles, diets high in fatty processed foods and other cultural reasons have made the diseases more prevalent in our global society. The International Diabetes Federation (IDF) predicts that at least one in 10 adults will have diabetes by 2030.

While that’s bad for society, it’s good for NVO stock’s bottom line. Novo first created an insulin product back in the 1920’s and is now the leading producer of the medicine. The firm has a 47% share when looking at the total insulin market worldwide.

Perhaps equally as impressive, NVO commands a 46% share when looking at modern and next-generation insulin.

That dominating position in a medicine that is required for diabetes sufferers to live has resulted in serious cash flows and profits over it history.

And with rates of diabetes continuing to grow across the globe and not just in Europe, investors can sit back and collect the firm’s high 2.6% dividend.

Source: Investor Place

[winston]

Novo Nordisk Slumps on Disappointing Profit, Guidance Cut

Novo Nordisk shares slumped after the world's largest diabetes drug maker reported disappointing fourth-quarter operating profits due to price pressure and increased competition in the U.S.

by Lisa Botter

Source: The Street

https://www.thestreet.com/story/1397593 ... yptr=yahoo

[winston]

Novo Nordisk Hits 2017 High After Q1 Profit Beat, Full-Year Guidance Boost

by Martin Baccardax

Novo Nordisk A/S (NVO) shares surged to a seven-month high Wednesday after the world's biggest maker of insulin posted stronger-than-expected first quarter earnings and boosted its full-year outlook.

Novo Nordisk said sales for the three months ending in March rose 5% to Dkr28.5 billion ($4.2 billion), beating the FactSet compiled consensus of Drk27.9 billion.

Operating profit for the quarter was also ahead of expectations, rising 10% to Dkr13.5 billion.

The group also raised the lower portion of its full-year operating profit forecast range by around one percentage point to between -1% and +3% compared for a previous estimate of -2% to +3%.

"With the performance in the first three months, we are well on track towards our targets for 2017," said CEO Lars Fruergaard Jorgensen.

"Sales were driven by our new, innovative products within diabetes and obesity care, and we are seeing the effects of our cost control initiatives, enabling us to invest in future growth opportunities."

Group sales of the company's suite of insulin products were marked at Dkr16.386 billion for the quarter, the company said, up 9% from the first three months of 2016. NovoRapid, its best-selling treatment, saw sales rise 15% to Dkr5.3 billion.

Novo Nordisk shares rose more than 7% by noon in Copenhagen to change hands at Dkr282.8 each, the highest since late September, extending their year-to-date gain to around 10% compared to a 7.24% advance the Stoxx Europe TMI Pharmaceuticals benchmark.

Source: The Street

https://www.thestreet.com/story/1411553 ... yptr=yahoo

[winston]

not vested

ANOTHER WINNER IN THE HEALTH CARE SECTOR

Today's chart highlights a leader in disease treatment...

Recently, we revisited our colleague Dave Eifrig's bullish call on health care stocks. For years now, he has said that the Baby Boomer generation will drive big gains in the sector.

As time goes on, they'll need more medicine, testing, and visits to the doctor. And the winners of this big trend are meeting that demand...

Today, we'll look at Novo Nordisk (NVO), the leading drugmaker to treat diabetes. As of 2015, more than 30 million Americans had diabetes... And according to the American Diabetes Association, the disease afflicts about 25% of seniors in the country.

Treating this serious condition is crucial – and Novo Nordisk is making strides. Over the past year, the company won some key regulatory approvals for new drugs, including a fast-acting insulin treatment for adults.

As you can see below, these victories fueled a huge rally... Shares are up more than 60% since the start of last year, and they recently hit a fresh 52-week high.

Diabetes is on the rise in America. And as the epidemic grows, more folks will rely on Novo Nordisk for treatment...

Source: Daily Wealth

[winston]

not vested

Stock Trade of the Week: Novo Nordisk (NVO)

by Rick Pendergraft

Suggested strategy: Buy NVO with a maximum entry price of $48. I would set a target of at least $72 over the next 12 months (for a potential return of 50%-plus from current prices).

I would suggest a stop loss at the $43 level.

Source: Daily Trade Alert

http://dailytradealert.com/2018/06/26/s ... rdisk-nvo/

[behappyalways]

Novo Nordisk Hits Record High After Study Finds Obesity Drug Wegovy Cuts Heart Risk
https://www.zerohedge.com/markets/novo- ... heart-risk

[behappyalways]

Novo Nordisk Shares Hit New Record As Wegovy Gets Approval In China
https://www.zerohedge.com/medical/novo- ... oval-china

[behappyalways]

Novo Shares Drop Most In Two Years On "Disappointing Ozempic & Wegovy Misses"
https://www.zerohedge.com/markets/novo- ... ovy-misses